|
Active substance |
Ipatasertib (MO40153) |
|
Holder |
Roche |
|
Status |
Closed |
|
Indication |
in combination with paclitaxel in PIK3CA/AKT1/PTEN altered, locally advanced or metastatic, triple-negative breast cancer or hormone-receptor-positive, HER2-negative breast cancer |
|
Public documents |
|
|
Last update |
24/09/2020 |
Ipatasertib
Last updated on 10/09/2024